aTyr Pharma To Present Efzofitimod Research At ATS 2025

aTyr Pharma, a clinical-stage biotechnology firm, will present findings about its leading medicinal candidate, efzofitimod, during the American Thoracic Society (ATS) 2025 International Conference. The event schedule for the American Thoracic Society 2025 International Conference spans from May 16 to May 21 in San Francisco. The organization will feature three posters at the event showing various features of pulmonary sarcoidosis, which is a critical condition in the lungs. The organizers will publish conference posters on aTyr's website following the presentation session at the ATS 2025 International Conference.

The first presentation will focus on EFZO-FIT, the largest placebo-controlled study on pulmonary sarcoidosis, outlining the trial's design and patient characteristics. The session will be held on  Monday, May 19, 2025, from 9:15 AM to 4:15 PM PT

The second session, titled The Inflamed Lung: Sarcoidosis and Autoimmune Disease Poster, will explore real-world treatment trends among U.S. patients with lung involvement. The date and time of the session is Sunday, May 18, 2025, from 9:15 AM to 4:15 PM PT. 

The third session, named Current Insights into Risk, Diagnosis, and Treatment of Occupational and Environmental Lung Diseases, will examine how common pulmonary sarcoidosis is in the U.S. and its impact on mortality. The third session will take place on Tuesday, May 20, 2025, from 9:15 AM to 4:15 PM PT. The posters will be displayed at the Moscone Center on different days throughout the conference, providing valuable insights into the disease and potential treatment approaches.